Skip to main content
    D

    Dianthus Therapeutics Inc. (DNTH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $86.98
    -2.57 (-2.87%)

    Market Cap: $5.04B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Dianthus Therapeutics Inc. (DNTH) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Dianthus Therapeutics (DNTH) has a market cap of $5.04B and an enterprise value of $4.99B. It kept -7107.03% of revenue as net income over the last 12 months. Its share count is up 51.72% from a year earlier.

    Total Valuation

    Enterprise value is 1.10% below the market cap, as cash exceeds debt.

    Market Cap$5.04B
    Enterprise Value$4.99B
    Latest price (Nov 17, 2026)$86.98

    Key Dates

    The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 8, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.34% in the quarter ended Sep 30, 2026 and grew 29.42% a year over 2 years.

    Shares Outstanding57.34M
    Shares Change (YoY)+51.72%
    Shares Change (QoQ)+2.34%
    Share Count Growth (2Y CAGR)+29.42%

    Price Statistics

    The stock is up 112.93% over 52 weeks and trades 0.75% below its 50-day average.

    Beta (1Y)0.99
    52-Week Change+112.93%
    1-Month Change+16.69%
    3-Month Change-23.50%
    6-Month Change+1.53%
    Total Return (1Y)+112.93%
    Total Return (3Y CAGR)+97.12%
    Return vs SPY (1Y)+101.52%
    Max Drawdown (1Y)-37.83%
    Max Drawdown (3Y)-53.48%
    Sharpe Ratio (1Y)1.34
    Correlation with SPY (1Y)0.24
    50-Day Average$87.64
    200-Day Average$87.27
    52-Week Range$35.84 to $117.88
    RSI (14 Days)51.6
    Average Volume (20 Days)838.54K

    Price chart

    Financial Position

    Current assets cover 30.02x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio30.02x
    Quick Ratio30.02x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -16.28% and return on assets is -15.84% over the last 12 months.

    Return on Equity (ROE)-16.28%
    Return on Assets (ROA)-15.84%
    ROA (5Y Average)-29.86%
    ROIC (5Y Average)-28.65%
    Asset Turnover0.00x
    Receivables Turnover8.27x

    Scores

    DNTH has an Altman Z-Score of 85.58, in the safe zone above 2.99, and a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Altman Z-Score85.58
    Altman Z ZoneSafe
    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $2.84M over the last 12 months is up 14.26% from the 12 months before.

    Revenue$2.84M
    Revenue Growth (YoY)+14.26%
    Gross Profit$2.84M
    Operating Income-$236.03M
    Pretax Income-$202.10M
    Net Income-$202.12M
    Reported EPS (TTM)-$3.99

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 96.88% of the $1.28B in total assets.

    Cash and Equivalents$55.69M
    Total Debt$0
    Net Cash$55.69M
    Net Cash Per Share$0.97
    Working Capital$827.52M
    Shareholder Equity$1.24B
    Book Value Per Share$21.65
    Total Assets$1.28B
    Total Liabilities$34.82M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $697.00K of capital spending, operating cash flow left -$175.85M of free cash flow.

    Operating Cash Flow-$175.15M
    Capital Expenditures$697.00K
    Free Cash Flow-$175.85M
    FCF Per Share-$3.14
    Depreciation and Amortization$8.48M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -8299.16%.

    Gross Margin100.00%
    Operating Margin-8299.16%
    Pretax Margin-7106.29%
    Net Margin-7107.03%
    FCF Margin-6183.23%

    Growth

    Revenue fell 31.80% a year over 3 years.

    Revenue Growth (3Y CAGR)-31.80%
    Book Value Per Share Growth (2Y CAGR)-40.82%
    Tangible Book Per Share Growth (2Y CAGR)-40.82%

    Revenue and profit by year

    Dividends and Yields

    DNTH does not pay a dividend. Its free cash flow yield is -3.53%.

    FCF Yield-3.53%
    Buyback Yield-3.15%
    Shareholder Yield-3.15%

    Stock Splits

    The last split was a 1-for-16 reverse split on Sep 12, 2023.

    Last Split DateSep 12, 2023
    Split TypeReverse split
    Split Ratio1:16

    Analyst Forecast

    Consensus estimates put revenue growth at -0.50% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-0.50%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About DNTH

    What is DNTH's market cap?

    Dianthus Therapeutics has a market cap of $5.04B. Its enterprise value, which adds debt and subtracts cash, is $4.99B.

    How many shares of DNTH are outstanding?

    Dianthus Therapeutics has 57.34M shares outstanding. The count is up 51.72% from a year earlier.

    Does DNTH pay a dividend?

    No. Dianthus Therapeutics does not pay a dividend.

    How much debt does DNTH have?

    Dianthus Therapeutics has $0 of total debt and $55.69M of cash and equivalents, a net cash position of $55.69M.